Pharming reports on Shareholders Meeting
(Thomson Reuters ONE) -
Leiden, The Netherlands, May 28, 2010. Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) announces that all items on
the agenda of today's Annual General Meeting of Shareholders (AGM) have been
approved by the Shareholders.
At the AGM, Dr. Sijmen de Vries, Chief Executive Officer of Pharming, presented
the 2009 results and the outlook of the Company for 2010. This presentation can
be found on the Pharming website. Main topics at the meeting were financing of
the Company, the progress on the European Marketing Authorization Application
(MAA) for Rhucin and the anticipated Day 210 EMA opinion on the MAA by end of
June, followed by the adoption of the opinion and the granting of the Marketing
Authorisation at Day 277 by the European Commission in Q3 2010. Management
confirmed its confidence on a positive outcome of the MAA process.
At the AGM, the majority of Shareholders voted in favour of the proposed items
on the agenda. The agenda included the proposal to increase the annual
remuneration of Pharming's CEO and the members of the Board of Supervisory
Directors. Both the members of the Board of Supervisory Directors, as well as
Pharming's CEO, voluntarily declined the proposed increases.
Mr. Jaap Blaak, Chairman of Pharming's Board of Supervisory Directors, said:
"Securing the Company's future and long-term value for our shareholders is our
first priority. Achieving financial stability is vital in order for Pharming to
reach its corporate goals. We highly appreciate management's efforts to improve
the financial situation of the Company and the position of the Company as a
whole."
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, ageing diseases, specialty products for surgical indications, and
nutritional products. Pharming's lead product Rhucin® for acute attacks of
Hereditary Angioedema has passed clinical development stage and the Market
Authorization Application is under review with the European Medicines Agency.
Prodarsan® - a product under development by Pharming's subsidiary DNage - is in
early stage clinical development for Cockayne Syndrome and lactoferrin for use
in food products. The advanced technologies of the Company include innovative
platforms for the production of protein therapeutics, technology and processes
for the purification and formulation of these products, as well as technology in
the field of DNA repair (via DNage). Recently the partial spin- out of DNage was
initiated. Additional information is available on the Pharming
website,http://www.pharming.com
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6
109 299 54
[HUG#1419553]
Press release (PDF): http://hugin.info/132866/R/1419553/369575.pdf
Unternehmensinformation / Kurzprofil:
Datum: 28.05.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 21600
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 250 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming reports on Shareholders Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
